Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models

10 Mar 2013

Abstract excerpt

BACKGROUND: Temozolomide (TMZ) is important chemotherapy for glioblastoma multiforme (GBM), but the optimal dosing schedule is unclear. METHODS: The efficacies of different clinically relevant dosing regimens were compared in a panel of 7 primary GBM xenografts in an intracranial therapy evaluation model. RESULTS: Protracted TMZ therapy (TMZ daily M-F, 3 wk every 4) provided superior survival to a placebo-treated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Metastases and Treatment
Share to Glioma Diagnosis and Treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23479134
DOI: 10.1093/neuonc/not010

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft modelsPMID 23479134Read ↗

MGMT in TMZ-based glioma therapy: Multifaceted insights and clinical trial perspectivesSemantic proximity Read ↗

Alkylpurine–DNA–N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patientsSemantic proximity Read ↗

Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft modelSemantic proximity Read ↗

Novel Imidazotetrazine Evades Known Resistance Mechanisms and Is Effective against Temozolomide-Resistant Brain Cancer in Cell CultureSemantic proximity Read ↗

The novel DNA cross-linking agent KL-50 is active against patient-derived models of new and recurrent post-temozolomide mismatch repair-deficient glioblastomaSemantic proximity Read ↗

From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas.Semantic proximity Read ↗

DNA methylation remodeling in temozolomide resistant recurrent glioblastoma: comparing epigenetic dynamics in vitro and in vivoSemantic proximity Read ↗

No benefit from TMZ treatment in glioblastoma with truly unmethylated MGMT promoter: Reanalysis of the CE.6 and the pooled Nordic/NOA-08 trials in elderly glioblastoma patientsSemantic proximity Read ↗

ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenograftsSemantic proximity Read ↗

Circadian regulation of <i>MGMT</i> expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastomaSemantic proximity Read ↗

Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment.Semantic proximity Read ↗

Temozolomide resistance in glioblastoma multiformeSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.